UNSPSC 51162313: Acetaminophen/chlorpheniramine/phenylpropanolamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER.

The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate.

UNSPSC 51162313 Acetaminophen/chlorpheniramine/phenylpropanolamine is a Commodity code whose recent activity centers on multi-source generic pharmaceuticals and over-the-counter products distributed through state and local government health and wellness programs, rather than procurement of the specific combination drug named in the code. State and local issuers soliciting under this code span cooperative purchasing alliances at the state level, county health departments, and subordinate health facilities. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP in January 2026 seeking manufacturers of generic pharmaceuticals and OTC products for distribution across participating state and local facilities. Seminole County, Florida released an IFB in June 2026 for naloxone and drug deactivation systems to support community health initiatives. Both procurements emphasize compliance with FDA requirements, current Good Manufacturing Practices, and the Drug Supply Chain Security Act, with vendors required to maintain relationships with authorized pharmaceutical wholesalers and demonstrate pricing flexibility through flat-fee, net-price, or WAC-minus formats.

Recent procurement activity under the code appears concentrated in the Upper Midwest and Southeast, with the MMCAP RFP covering Minnesota and Oregon and the Seminole County opportunity in Florida. The MMCAP RFP (S1070000015802) is due March 26, 2026, and requires responses through the ePro procurement system with pricing and product information in CSV format; evaluated vendors will supply products through AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC, with contracts effective July 1, 2026. The Seminole County IFB (IFB60459723LAS), posted June 30, 2026, seeks annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to the Seminole County Community Health Building, with a response deadline of July 26, 2023, and an initial two-year term plus one-year renewal option. Both solicitations require E-Verify compliance, drug-free workplace certification, and comprehensive insurance coverage; the MMCAP RFP weights price competitiveness at 75 percent of evaluation criteria, while specific set-aside designations are not identified in either opportunity.